Dishman Carbogen Amcis subsidiary clears US FDA inspection without observations
- Carbogen Amcis AG cleared its first US FDA inspection at the Vionnaz, Switzerland site
- No observations or Form 483 notices were issued during the audit
- Inspection concluded on September 11, 2026
- Disclosure made under SEBI LODR Regulations 30 and 51
- Company confirms all global sites remain approved by major regulators

*this image is generated using AI for illustrative purposes only.
Dishman Carbogen Amcis announced that its wholly owned subsidiary, Carbogen Amcis AG, successfully completed its first US Food and Drug Administration inspection at its manufacturing site in Vionnaz, Switzerland.
The inspection concluded on September 11, 2026, with no observations raised by the regulator. The facility did not receive a Form 483 notice, which is typically issued for significant violations or deficiencies found during such audits.
Regulatory Compliance
The company disclosed the outcome pursuant to Regulations 30 and 51 of the SEBI (LODR) Regulations, 2015. The successful clearance underscores the subsidiary’s adherence to strict quality parameters required for the US market.
Dishman Carbogen Amcis stated that this result reflects the company’s strong focus on quality across its global operations. All manufacturing sites worldwide remain approved by major regulatory agencies.
What the Numbers Show
The absence of a Form 483 is a critical operational indicator. In pharmaceutical manufacturing, receiving no observations during a first-time FDA inspection suggests robust process validation and quality control systems are already in place, reducing the risk of future regulatory holds or export bans for products manufactured at the Vionnaz facility.
Historical Stock Returns for Dishman Carbogen Amcis
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.14% | -5.50% | -11.18% | +1.67% | -38.45% | 0.0% |
How might the successful FDA inspection of the Vionnaz facility impact Dishman Carbogen Amcis's ability to secure new US-based API contracts in 2027?
Will this regulatory clearance accelerate the commercialization timeline for any specific drug candidates currently under development at the Swiss site?
What is the expected contribution of the Vionnaz facility to the company's overall revenue growth over the next three fiscal years?


































